About Celsis In Vitro Technologies

Increasing discovery. Advancing development.
Leading provider of In Vitro and ADME-Tox Products.

Celsis In Vitro Technologies (IVT) provides high quality, value-added in vitro products and services. We can immediately add value to your drug discovery and preclinical development program by providing large lot sizes and data sets of hepatocytes, other cell types, and subcellular fractions along with associated media products. In addition, our experienced staff will work with you to ensure consistent results.

Capitalizing on the efficiencies of in vitro models and methods significantly decreases your investment in finances and resources for drug discovery and preclinical development studies. Celsis IVT's innovation and expertise creates a multifaceted offering that will add value by meeting your evolving research needs.

Celsis International plc

acquired In Vitro Technologies

Inc (IVT) on the 20 July 2006.

The synergies created by

joining forces has created a

stronger team with great

future potential.

For more information about the

acquisition please visit the

Celsis press releases page.